Literature DB >> 16055820

A guide to cost-effectiveness acceptability curves.

Elisabeth Fenwick, Sarah Byford.   

Abstract

Use of cost-effectiveness acceptability curves, as a method for summarising information on uncertainty in cost-effectiveness, has become widespread within applied studies. This includes several studies in the mental health field. This editorial uses examples from recent papers to illustrate how cost-effectiveness acceptability curves are constructed, what they represent and how they should be interpreted.

Mesh：

Year:  2005        PMID： 16055820     DOI： 10.1192/bjp.187.2.106

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  147 in total

1.  Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.

Authors:  Richard Edlin; Jeff Round; Claire Hulme; Christopher McCabe
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Authors:  Naiyana Praditsitthikorn; Yot Teerawattananon; Sripen Tantivess; Supon Limwattananon; Arthorn Riewpaiboon; Saibua Chichareon; Nantakan Ieumwananonthachai; Viroj Tangcharoensathien
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

3.  Moving from efficacy to effectiveness trials in prevention research.

Authors:  Erica Marchand; Eric Stice; Paul Rohde; Carolyn Black Becker
Journal:  Behav Res Ther       Date:  2010-11-02

4.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 5.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49.

Authors:  Richard P A Norman; D Gareth Evans; Douglas F Easton; Kenneth C Young
Journal:  Eur J Health Econ       Date:  2007-03-09

7.  Model fidelity of assertive community treatment for clients with first-episode psychosis: a target group-specific application.

Authors:  M J M Verhaegh; I M B Bongers; H Kroon; H F L Garretsen
Journal:  Community Ment Health J       Date:  2008-10-16

8.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

9.  Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.

Authors:  Demetrios N Kyriacou; Debra Dobrez; Jorge P Parada; Justin M Steinberg; Adam Kahn; Charles L Bennett; Brian P Schmitt
Journal:  Biosecur Bioterror       Date:  2012-07-30

10.  The effectiveness of joint crisis plans for people with borderline personality disorder: protocol for an exploratory randomised controlled trial.

Authors:  Paul Moran; Rohan Borschmann; Clare Flach; Barbara Barrett; Sarah Byford; Joanna Hogg; Morven Leese; Kim Sutherby; Claire Henderson; Diana Rose; Mike Slade; George Szmukler; Graham Thornicroft
Journal:  Trials       Date:  2010-02-23       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.